defiteli注意事项

Approved for marketing in the EU in October 2013 (also called defibrinoside in China), it has anti-thrombotic, fibrinolytic, anti-ischemic and anti-infective effects in vivo and in vitro. The results of multiple clinical studies indicate that defibrotide is a safe and effective drug for preventing and treating HVOD after HSCT.

The recommended dose of defiteli for adult and pediatric patients is 6.25 mg/kg administered every 6 hours as a 2-hour intravenous infusion. Must be diluted before infusion. Do not coadminister with other intravenous medications at the same time and in the same intravenous line.

As an injectable drug, defiteli must be used strictly. The precautions for defiteli are as follows:

1. Bleeding:

Defiteli (defibrinoside) increases plasmin activity in vitro, and sputum may increase the risk of bleeding after hematopoietic stem cell transplantation (HSCT) in patients with VOD. Do not initiate defibrotide in patients with active bleeding. Monitor patients for signs of bleeding. If bleeding occurs in a patient taking defiteli, discontinue defibrotide, treat the cause, and provide supportive care until bleeding has stopped.

Concomitant use of defiteli and a systemic anticoagulant or fibrinolytic therapy (excluding use for routine maintenance or central venous line reopening) may increase the risk of bleeding. Discontinue anticoagulants and fibrinolytics before defiteli therapy, and consider delaying initiation of defiteli administration until the effects of the anticoagulant have lessened.

2. Hypersensitivity reaction:

Hypersensitivity reactions have occurred in less than 2% of patients treated with defibrinoside. These reactions include rash, urticaria, and angioedema. One case of allergic reaction was reported in a patient who had previously received defiteli. Monitor patients for hypersensitivity reactions. Especially if there is a history of previous exposure. If a serious hypersensitivity reaction occurs, discontinue use and follow standard medical care and monitor until symptoms resolve.